Siemens Healthineers : Meet-the-Management – November 17, 2020

Meet the Management

Virtual edition

17 November 2020

Unrestricted © Siemens Healthineers, 2020

Table of contents

Meet the Management 2020

1. Imaging
2. Diagnostics
3. Advanced Therapies

2

Unrestricted © Siemens Healthineers, 2020

Meet the Management 2020

IM

Continuously innovating and making new markets

Imaging

André Hartung

President Diagnostic Imaging

3

Unrestricted © Siemens Healthineers, 2020

Imaging will continue outperforming and shaping the market

Recent highlights are substantial to …

CT SOMATOM X.cite

Intelligent

YSIO X.pree

with myExam Companion

A new era of X-ray

Imaging

Intelligent user guidance,

imaging, recently

90% of the cardiac scans

received FDA clearance

are carried out with the

in U.S.

settings suggested

Streamlined

AI-Rad Companion

Operations

syngo Virtual Cockpit

Gaining commercial

Enabling remote / safe

traction, >100k cases

scanning assistance and

processed; 4 new

increased throughput,

Companions released

current roll-out in 16

AI-

countries with >160 connects

AI-Pathway

Powered

Teamplay digital

Companion

Clinical

health platform

Commercial

Decisions

New irresistible

successes in major

applications leading to

U.S. accounts

>30,000 connected devices

1 Y-o-y on a comparable basis, excluding translation and portfolio effects

Meet the Management 2020

IM

… our Upgrading ambition

>5%

revenue growth1

Gain

market share

Steady

service growth

Expand

and lead

4

Unrestricted © Siemens Healthineers, 2020

Digitalization is driving our innovation strategy

and continuously creating value …

Syngo Carbon

The connecting element that gives rise to knowledge

MAGNETOM Free.Max	AI-Rad Companion
Breaking Barriers	Bringing AI into clinical
in MRI	routine

Meet the Management 2020

IM

Photon Counting

Introducing a new era of

Computed Tomography

Today

Tomorrow

… to informed decision making

These products are partially still under development and not yet commercially available. Their future availability cannot be guaranteed.

5

Unrestricted © Siemens Healthineers, 2020

MAGNETOM Free.Max

Breaking Barriers in MRI

Intelligent Imaging	Streamlined Operations	AI-Powered Clinical Decisions

• Leveraging digitalization to simplify MRI with myExam Companion: guidance and automation enable high-quality MR exams regardless of operator's skill level
• Making access affordable: minimal siting requirements drastically reduce installation cost and virtually helium- free magnet reduces operating cost
• World's first 80cm bore sets a new paradigm in patient comfort
• Creating access to new markets for MRI
  e.g. point of care such as urgent care centers, orthopedics or ICU

Breaking Barriers for MRI in affordability, in addressing new clinical fields and bringing it to spaces where it has never been before

Meet the Management 2020

IM

MAGNETOM Free.Max

New launch

The product is still under development and not yet commercially available. Its future availability cannot be guaranteed.

6

Unrestricted © Siemens Healthineers, 2020

Syngo Carbon

The connecting element that gives rise to knowledge

Meet the Management 2020

IM

Intelligent Imaging	Streamlined Operations	AI-Powered Clinical Decisions

• Transforming reading and reporting - integration from acquisition to final reporting over the entire radiology workflow
• Driving efficiency via data integration into one enterprise imaging solution to increase operational value and clinical quality
• Upgrading potential for >20k syngo sites worldwide

Scalable deployment and consolidation of IT assets with

recurring business streams

Syngo Carbon

New launch

The product is still under development and not yet commercially available. Its future availability cannot be guaranteed.

7

Unrestricted © Siemens Healthineers, 2020

AI-Rad Companion

Bringing AI into clinical routine

Intelligent Imaging	Streamlined Operations	AI-Powered Clinical Decisions

• Supporting radiologists to handle steadily increased procedure volumes while improving quality and speed of diagnosis
• Speeding-upthe workflow, e.g. with AI-RadCompanion Organs RT (Radiation Therapy) drastically reduced organ contouring time from 20 to 2 minutes1
• Increasing quality: ~97% of processed cases are confirmed without further physician correction2
• COVID-19prototype "CT Pneumonia Analysis" with >80.000 processed case. Now commercially available with AI-Rad Companion Chest CT3 4

Scalability with new clinical extension expanding over the entire human anatomy, three new extension in FY21.

Turning into continuously increasing recurring revenue streams

Meet the Management 2020	IM

Some AI-Rad Companion products are not commercially available in all countries. Their future availability cannot be guaranteed.

1 Customer statement is based on results that were achieved in the customer's unique setting. Because there is no "typical" hospital or laboratory and many variables exist (e.g., hospital size, samples mix, case mix, level of IT and/or automation adoption) there can be no guarantee that other customers will achieve the same results. | 2 Data on file. | 3 with feature Pulmonary Density | 2 Prototype and Pulmonary Density feature without FDA clearance; results are not indicated for the diagnosis of COVID-19

8

Unrestricted © Siemens Healthineers, 2020

Photon Counting: A quantum leap in innovation, introducing a new era of Computed Tomography

Meet the Management 2020

IM

Intelligent Imaging	Streamlined Operations	AI-Powered Clinical Decisions

Photon Counting	Future

4 mm Stent

Current

Technology

Photon

Counting CT

The product is still under development and not yet commercially available. Its future availability cannot be guaranteed. 1 Results are based on bench tests in our own lab; data on file.

The future of Intelligent Imaging for Computed Tomography

• Significantly more details with ultra-highspatial resolution (2x higher compared to current technology)1
• Drastically lower patient dose, up to 50% less1
• Providing multi-energy information with every scan
• Clinical evaluation phase with luminary customers to be started in FY21

Today

Tomorrow

9

Unrestricted © Siemens Healthineers, 2020

Meet the Management 2020

IM

It's time for your questions

Q&A

10

Unrestricted © Siemens Healthineers, 2020

Meet the Management 2020

DX

New levels of productivity and digitalization for the clinical lab

Diagnostics

Deepak Nath

President Laboratory Diagnostics

11

Unrestricted © Siemens Healthineers, 2020

Global healthcare trends are shaping the evolution of Diagnostics market

Bifurcation

Meet the Management 2020

DX

of the market

Increasing demand for diagnostic tests

Consolidation

and industrialization

Increased

clinical integration

Customer pain points	Customer pain points
•	Form factor/menu	•	Productivity
•	Holistic data management	•	Space efficiency
•	Time to informed action	•	Staff shortage

	Relative
	growth	Accelerated
	rates
	by COVID

POC POL1	POC	Small	Large	Reference
and Clinics	Hospital	Hospital Labs	Hospital Labs	Labs

	12
1 POC = Point-of-Care, POL = Physician Office Lab	Unrestricted © Siemens Healthineers, 2020

COVID-19 impacted performance - improvement expected in FY21

Grow Expand Elevate

Delivering on the promise of Atellica

						Development of adjusted EBIT
						margin (illustrative)
FY19	Volume	COVID-19	Atellica	Other	FY20	FY21

Meet the Management 2020

DX

COV2T antibody test1

COV2 Rapid Antigen Test2

SARS-CoV-2RT-PCR1

Performance in FY20 significantly impacted by COVID

• Severe decline in routine care testing, partial recovery in Q4
• Continued "investment" in service and maturing Atellica systems: foundational to margin improvement in FY21, high seeding rates for Atellica instruments

Outlook FY21: improvement expected in both top and bottom line

• Routine care recovers but remains below 2019 levels
• Good progress in maturing of
  Atellica platform
• Improved factory utilization
• Strengthened leadership team

We reacted adeptly to the crisis

• Robust portfolio of COVID tests → high quality COVID-19antibody test
• Positioned to substantially participate if uptake of antibody testing materializes
• Potential upside with lateral flow antigen; lab based antigen testing Q2/Q3

1 This test has not been FDA cleared or approved. This test has been authorized by FDA under an EUA for use by authorized laboratories. | 2 Not available for sale in the U.S. Product availability may vary from country to country and is subject to varying regulatory requirements.

13

Unrestricted © Siemens Healthineers, 2020

Our portfolio innovations will deliver the lab of the future

Grow Expand Elevate

Workflow excellence

Clinical

excellence

Meet the Management 2020

DX

Lead in workflow and achieve clinical excellence

Positioning ourselves for the future	Innovating in workflow
•	Deliver further Atellica innovations incl. Mid-Volume system (CI19001)	• Enhance and expand Atellica Solution IT
•	Launch assays to continue menu enrichment	• Strengthen laboratory automation offerings

1 In development. Future availability cannot be guaranteed.

14

Unrestricted © Siemens Healthineers, 2020

Meet the Management 2020

DX

It's time for your questions

Q&A

15

Unrestricted © Siemens Healthineers, 2020

Meet the Management 2020

AT

Pushing the limits of image-guided procedures

Advanced Therapies

Michel Therin

President Advanced Therapies

16

Unrestricted © Siemens Healthineers, 2020

Upgrading ambitions confirmed

Defining the next level of image-guidance

by integrating robotics and imaging and improving clinical relevance

New generation of Image-Guidance

• Connected and digital interventional suite
• Maximize ROI with improved lab utilization and interdisciplinary usage
• Disruptive potential for stroke treatment

New generation of

Treatment Delivery

• Protection for patients and staff

• Improved robotic procedural precision

• Procedure intelligence and automation

• Potential to enable remote treatment

1 Y-o-y on a comparable basis, excluding translation and portfolio effects

Meet the Management 2020

AT

Comparable revenue growth1

>5%

revenue growth

Gain

market share

Steady

service growth

Expand

and lead

17

Unrestricted © Siemens Healthineers, 2020

ARTIS icono exceeds our and customer expectations with strong market acceptance

	Meet the Management 2020	AT
Excellent image quality to visualize smallest details	Penetration almost twice as
and fine structures	fast as predecessor launch

Number of sold systems

40% faster to 100 units

Optimized device visualization

Visualization of hyperdense tumors

ARTIS	Previous	Time
after
icono	platform
launch

Right image: Courtesy of Prof. Florian Wolf, MD, Prof. Christian Loewe, MD, Allgemeines Krankenhaus Wien - Medical University Vienna, Austria;

Left image: Courtesy of University Hospital Aalborg, Denmark

18

Unrestricted © Siemens Healthineers, 2020

Corindus: Continued market creation in a tough environment reinforcing our value proposition

Expanding the value proposition

-20%	Reduction in radiation exposure for
patients in robotic PCI1

Opportunity4 to reduce infectious disease exposure through

"procedural distancing"

Customers addressed in robotic

1k+ webcasts since pandemic

Pioneering new pathways

1st

ever

Transcontinental simulated telerobotic PCI over 5G, Fiber, public internet2,5

Toronto performs first robotic-assisted aneurysm coiling in patient3,5

Meet the Management 2020

AT

Moving forward

Strategic vision re-

confirmed

Continued commitment to pioneer the space

of endovascular robotics

Performance

within projected corridor

Integrated development of

imaging and robotics

1 Patel E., et al. Circ Cardiovasc Interv, 2020, 20% radiation reduction to patients shown in single-center study. | 2 Madder R., et al. Catheter Cardiovasc Interv, 2020 |

3 Pereira V., et al. J NeuroIntervent Surg, 2020 | 4 https://cardiovascularnews.com/covid-19-robotics-may-help-to-reduce-exposure-to-virus-patients-during-interventional-procedures/ | 5 The product is still under development and not commercially available yet

19

Unrestricted © Siemens Healthineers, 2020

Establishing the foundation to advance stroke treatment

Meet the Management 2020

AT

20%	Only 10%
Procedure growth1	of thrombectomy eligible population in
	the US receive mechanical thrombectomy2

FY19	FY20	FY21	FY21	FY22
First in-human remote	First transcontinental remote	First clinical trial on	Begin of integrated	Initiate first
clinical case3,4	simulated cases5	robotic neuro	development, e.g., joint	REMOTE ROBOTIC
		procedures	user interface, guidance
		CLINICAL TRIALS3
			and tracking features

Boston

Spokes

Spokes

3,087 miles

San Francisco

Hub

1 CAGR 2013-2024: DRG Medtech 360 report 2018, Canaccord Genuity Analyst Report (May 2019) | 2 In the US, Rai AT, et al., J Neurointervent Surg (9) 2017 | 3 Based on CorPath GRX for PCI procedures | 4 www.thelancet.com/journals/eclinm/article/PIIS2589-5370(19)30137-3/fulltext | 5 Madder R., et al. Catheter Cardiovasc Interv., 2020; Image: Courtesy of Jan Gralla, MD, Pasqulae Mordasini, MD, Department of Neuroradiology, Inselspital, Bern, Switzerland

20

Unrestricted © Siemens Healthineers, 2020

Meet the Management 2020

AT

It's time for your questions

Q&A

21

Unrestricted © Siemens Healthineers, 2020

Thank you for your attention

Unrestricted © Siemens Healthineers, 2020